Patent Filing

The FDA is reviewing a new, more affordable alternative to the costly arthritis drug Orencia, potentially saving patients and the healthcare system billions.

Safe Pro Group's AI-powered edge systems are heading to the U.S. Government, a key validation, yet market reaction raises questions about the deal's size.

As Sectra prepares its nine-month report, all eyes are on its performance as a key indicator for the converging medical IT and cybersecurity sectors.

A federal court ruling against Corcept Therapeutics clears a key legal hurdle for Teva's generic Cushing's syndrome drug, rattling investors.

Element Biosciences unveils VITARI, a high-throughput benchtop sequencer promising a $100 whole genome, challenging market giants and democratizing genomics.

Oculis appoints former Cooley partner Katie Kazem as CLO, a strategic move to fortify governance ahead of pivotal data readouts for its late-stage eye drugs.

The biotech firm enacts a 1-for-25 stock split to avoid delisting, placing its promising cancer therapy pipeline under a brighter, more critical spotlight.

A new oral drug, IMSB301, offers hope for Aicardi Goutières Syndrome, a devastating rare disease with no cure, in a pivotal new clinical trial.

With a 135% revenue surge and a key FDA submission for its kidney transplant drug, Hansa Biopharma is poised for a pivotal year of expansion.

Aucta Pharma launches two rare disease drugs, PYQUVI and ZELVYSIA, betting on a 'branded-generic' model to navigate highly competitive markets.

With major drug approvals on the horizon, Nuvalent's leadership will detail its strategy for its next-gen cancer therapies at an influential investor summit.

Shareholders to vote on a US$3.65 per share all-cash deal, a significant premium that will take the growing respiratory care provider private.

X-BATT's new patent aims to reduce fire risk in lithium-ion batteries, boosting consumer trust and unlocking new markets for the technology.

A nationwide study, with NFL legend Steve Gleason as Participant #1, seeks to uncover why high-performance groups face a disproportionate risk of ALS.

NurExone appoints Eyal Gabbai, a healthcare and finance heavyweight, to its board, signaling a strategic pivot from R&D to market execution for its therapies.

Quetzal Therapeutics’ oral capsule for a rare leukemia could replace grueling IVs. The FDA's Fast Track status signals a major shift for patients and investors.

With drug pipelines facing staggering failure rates, HKeyBio's new preclinical strategy aims to de-risk R&D and accelerate effective new treatments.

A Texas court dismisses all claims against entrepreneur Tahir Javed, revealing a deeper story of political rivalry and alleged online misinformation.

A new FDA-cleared test detects RSV, Flu A/B, and COVID from a single swab, offering a powerful diagnostic tool for families, especially for infants.

Swedish biotech innovator Hansa Biopharma wins a top award for its life-saving transplant tech, facing a pivotal year with FDA review on the horizon.